Protective effect of hydroxychloroquine in systemic lupus erythematosus.                 Prospective long-term study of an Israeli cohort{

Molad, Yair; Gorshtein, Alexander; Wysenbeek, A J; Guedj, D; Majadla, Riad; Weinberger, Abraham; Amit-Vazina, Mirit

doi:10.1191/0961203302lu203ra

Cited by 127 publications

(97 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of hydroxychloroquine has been shown to have cardioprotective effect as it has suggested that it has antiatherogenic effects [16,17]. Generally, the treatment for myocardial infarction, pulmonary hypertension and valvular disease are similar as those without APLS.…”

Section: Short Communicationmentioning

confidence: 99%

Cardiac Manifestations on Anti-Phospholipid Syndrome

Ah¹

2017

J Clini Nephrol

View full text Add to dashboard Cite

Section: Short Communicationmentioning

confidence: 99%

Cardiac Manifestations on Anti-Phospholipid Syndrome

Ah¹

2017

J Clini Nephrol

View full text Add to dashboard Cite

“…Активность болезни и выраженность обострения во время проведения исследования также предшествовали нара-станию степени повреждения в гонконгской когорте [32]. Прямая связь между высокой активностью и развитием по-вреждений выявлена и в других исследованиях [21,41].…”

Section: и н д е к с п о в р е ж д е н и я S L I C C ( S Y S T E M I unclassified

Irreversible organ damages in patients with systemic lupus erythematosus. SLICC damage index

Соловьева¹,

Асеева²,

Лисицына³

et al. 2016

RJTAO

View full text Add to dashboard Cite

Системная красная волчанка (СКВ) -мультисистемное аутоиммунное заболевание с различными клиническими проявлениями, длительным течением и непредсказуемым исходом. За последние десятилетия 10-летняя выживаемость больных СКВ превысила 90%, в связи с чем одной из наибо-лее актуальных задач лечения и мониторинга этих пациентов становится предотвращение необратимых повреждений ор-ганов и улучшение качества жизни. Количество различных повреждений, как правило, ассоциируется с длительностью и высокой активностью болезни, а также лекарственной тера-пией. Особенно важным является соблюдение баланса меж-ду полноценным подавлением активности СКВ, особенно в тяжелых случаях, и минимизацией токсичности применяе-мых препаратов. В то же время нельзя забывать, что у некото-рых пациентов ни один из этих факторов не приводит к раз-витию повреждения, что подчеркивает важность проблемы и необходимость индивидуального контроля у пациентов с СКВ. В стандарты для проведения клинических исследова-ний включены три основных параметра оценки СКВ: актив-ность болезни, повреждение органов и качество жизни, свя-занное со здоровьем [1]. Необходимость в надежном инстру-менте для оценки кумулятивных повреждений органов при-

show abstract

“…They also reduce mortality 12-14 and the number of flare-ups 15 as well as limit damage to various organs. 16,17 Metabolic benefits of HCQ and CQ are presented in TAbLE 1. They have an antiaggregatory effect, particularly in SLE associated with antiphospholipid syndrome, 11 and hypolipemic effect.…”

Section: Review Articlementioning

confidence: 99%

New treatment strategy including biological agents in patients with systemic lupus erythematosus

Leszczyński¹,

Pawlak-Buś²

2013

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a heterogeneous disease, in which B lymphocyte activation and chronic inflammation play the key role. Both the disease itself and its treatment cause damage to multiple organs and systems. So far, despite intensive treatment, disease remission has been achieved in few patients, and the ratio of organ complications has increased significantly. This is caused by a long-term glucocorticoid therapy with a relatively rare use of immunosuppressive drugs. With a new treatment strategy and modern immunotherapy, it is possible to reduce the mortality rate, limit multiple--organ damage, thereby significantly improving the quality of life and prognosis of patients with SLE. The "treat-to-target" strategy enables targeted treatment resulting in a long-term symptom remission. It is based on an intensive immunosuppressive treatment with simultaneous reduction of glucocorticoid doses, and limiting their use solely to exacerbations in disease activity. The current idea for treatment is also the conscious use of the beneficial potential of background SLE treatment including antimalarial agents and standard immunosuppressive therapy. With the first biological agent approved for SLE treatment, the new age of therapy has dawned. Biologics offer new prospects and possibilities to induce clinical and immunological remission of SLE. KEy WoRdsantimalarial drugs, biological therapy, immunosuppressive therapy, new treatment strategy, systemic lupus erythematosus

show abstract

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{

Cited by 127 publications

References 34 publications

Cardiac Manifestations on Anti-Phospholipid Syndrome

Cardiac Manifestations on Anti-Phospholipid Syndrome

Irreversible organ damages in patients with systemic lupus erythematosus. SLICC damage index

New treatment strategy including biological agents in patients with systemic lupus erythematosus

Contact Info

Product

Resources

About